Filters

Pp-245 manufacturers

Filters

None products found

pp-245

Tablets

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Progressive and tophaceous gout / Clinical stage: Phase 3 / Modality: URAT1 inhibitor (next-generation urate-lowering agent) / Mechanism & Target: URAT1 transporter inhibition / Route & form: Oral, once-daily dosing / Differentiation: Next-generation URAT1 inhibitor; two fully recruited Phase 3
Manufacturer #6157
Specialty biopharmaceutical company focused on rare hematological, immunological, and inflammatory diseases. Develops targeted biologics and small molecules for high unmet medical need conditions. Advances Phase 3 programs through a global development and commercialization network.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.